| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/FON.12.50 |
| P698 | PubMed publication ID | 22646772 |
| P50 | author | Lisa Pieri | Q37830543 |
| Paola Guglielmelli | Q37830547 | ||
| P2093 | author name string | Alessandro M Vannucchi | |
| Maria Chiara Susini | |||
| P2860 | cites work | Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. | Q54426186 |
| Possible new LNK mutations in myeloproliferative neoplasms. | Q54559825 | ||
| EZH2 mutational status predicts poor survival in myelofibrosis. | Q54560112 | ||
| LNK mutations in JAK2 mutation-negative erythrocytosis. | Q54649906 | ||
| Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera | Q58416020 | ||
| The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes | Q22299206 | ||
| JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis | Q24609999 | ||
| Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy | Q24631288 | ||
| Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 | Q27687464 | ||
| Efficacy and safety of low-dose aspirin in polycythemia vera | Q28166691 | ||
| Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia | Q28182916 | ||
| Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera | Q28210331 | ||
| Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study | Q28211348 | ||
| The haematocrit and platelet target in polycythemia vera | Q28212137 | ||
| Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia | Q28213633 | ||
| Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention | Q28219237 | ||
| Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes | Q28221962 | ||
| A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera | Q28241887 | ||
| Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis | Q29614337 | ||
| Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders | Q29614510 | ||
| A gain-of-function mutation of JAK2 in myeloproliferative disorders | Q29618851 | ||
| Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders | Q29618853 | ||
| Mutation in TET2 in myeloid cancers | Q29619292 | ||
| JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. | Q33371084 | ||
| Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele | Q33385124 | ||
| Pomalidomide is active in the treatment of anemia associated with myelofibrosis | Q33385644 | ||
| Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis | Q33386057 | ||
| Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis | Q33391880 | ||
| Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients | Q33392291 | ||
| A phase-2 trial of low-dose pomalidomide in myelofibrosis | Q33392689 | ||
| DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status | Q33393245 | ||
| Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis | Q33393587 | ||
| Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study | Q33394025 | ||
| Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis | Q33397838 | ||
| JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis | Q33399977 | ||
| A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 | ||
| Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients | Q33609532 | ||
| Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. | Q34074931 | ||
| Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel | Q34626628 | ||
| The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). | Q34725589 | ||
| MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia | Q34770384 | ||
| Polycythemia vera: myths, mechanisms, and management | Q34977300 | ||
| The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation | Q35849342 | ||
| Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model | Q35849674 | ||
| Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. | Q36003480 | ||
| FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia | Q36183556 | ||
| DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms | Q36267848 | ||
| Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis resear | Q36702208 | ||
| A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. | Q36717896 | ||
| Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution | Q36779588 | ||
| Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera | Q36938773 | ||
| Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. | Q36941052 | ||
| Thrombocytosis and thrombosis | Q37007426 | ||
| Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. | Q37127245 | ||
| The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal | Q37133762 | ||
| Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis | Q37163487 | ||
| Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. | Q37163590 | ||
| Genetic complexity of myeloproliferative neoplasms. | Q37255024 | ||
| Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. | Q37289795 | ||
| The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera | Q37406784 | ||
| Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. | Q37412790 | ||
| How I treat symptomatic splenomegaly in patients with myelofibrosis | Q37427166 | ||
| Advances in understanding and management of myeloproliferative neoplasms | Q37445395 | ||
| How I treat myelofibrosis | Q37825719 | ||
| Therapeutic approaches in myelofibrosis. | Q37860336 | ||
| New mutations and pathogenesis of myeloproliferative neoplasms. | Q37886439 | ||
| Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. | Q37900078 | ||
| Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. | Q37934479 | ||
| Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. | Q38329285 | ||
| Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia | Q39520608 | ||
| The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis | Q40265956 | ||
| Vascular and neoplastic risk in a large cohort of patients with polycythemia vera | Q40445951 | ||
| The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. | Q40463923 | ||
| Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. | Q41283205 | ||
| Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation | Q42200351 | ||
| Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia | Q42628740 | ||
| LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations | Q42931701 | ||
| Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. | Q43010173 | ||
| Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria | Q43061082 | ||
| Taxing sugar-sweetened beverages | Q43180928 | ||
| A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process | Q43237567 | ||
| Mutations of ASXL1 gene in myeloproliferative neoplasms. | Q43456344 | ||
| Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. | Q43898090 | ||
| Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. | Q44174767 | ||
| Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden | Q44900430 | ||
| Primary health and supportive care needs of long-term cancer survivors: a questionnaire survey | Q45218852 | ||
| Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders | Q45310345 | ||
| Risk factors for leukemic transformation in patients with primary myelofibrosis | Q46650489 | ||
| Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice | Q46832173 | ||
| Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early primary myelofibrosis | Q47805850 | ||
| Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms | Q47960630 | ||
| The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients | Q48680927 | ||
| Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. | Q50528661 | ||
| Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. | Q51025938 | ||
| Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. | Q51848454 | ||
| Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. | Q53147067 | ||
| International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. | Q53162984 | ||
| Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. | Q53166045 | ||
| Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. | Q53184342 | ||
| JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. | Q53185401 | ||
| MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. | Q53362332 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 575-593 | |
| P577 | publication date | 2012-05-01 | |
| P1433 | published in | Future Oncology | Q2781597 |
| P1476 | title | BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques | |
| P478 | volume | 8 |
| Q37623156 | A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms |
| Q37168138 | JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms |
Search more.